Search - tctmd.com

Displaying 1 - 20 of 93

Sort: Relevancy | Date

News Daily News

Top Endovascular News of 2024

L.A. McKeown

December 28, 2024

News Conference News TCT 2024

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

L.A. McKeown

October 29, 2024

News Industry News

Cordis Announces Positive 24-Month Results from Superficial Femoral Artery Study, Confirming Sustained Benefits of SELUTION SLR™ (sustained limus release) Drug-Eluting Balloon in Complex Patients

June 18, 2024

News Conference News SCAI 2024

No Sex-Specific Differences in PAD Therapy Outcomes: REVIVE Analysis

L.A. McKeown

May 10, 2024

News Daily News

Popliteal Interventions Linked to Higher Long-term Amputation Risk Than SFA

L.A. McKeown

July 11, 2023

News Conference News LINC 2023

PROSPECT MONSTER: Real-World Data Confirm Low-Dose DCB Efficacy in PAD

L.A. McKeown

June 21, 2023

News Conference News VIVA 2022

TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years

L.A. McKeown

November 03, 2022

News Daily News

IVUS Useful in Many Peripheral Intervention Scenarios, Consensus Document

L.A. McKeown

August 05, 2022

News Daily News

Five-Year Paclitaxel DCB Data Attest to Long-term Safety, Efficacy

L.A. McKeown

June 01, 2022

News Conference News SCAI 2022

DISRUPT PAD III: Lithotripsy Prep Linked to Better PAD Patency at 1 Year

L.A. McKeown

May 23, 2022

News Daily News

Routine IVUS in Peripheral Interventions Supported by Small RCT

L.A. McKeown

March 09, 2022

News Conference News VIVA 2021

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

L.A. McKeown

October 12, 2021

News Conference News ACC 2021

SAFE-PAD Throws More Doubt on the Paclitaxel Mortality Signal

L.A. McKeown

May 16, 2021

News Daily News

No Long-term Mortality Risk for Paclitaxel-Based Peripheral Devices: Medicare Advantage Cohort

L.A. McKeown

June 29, 2020

News Conference News LINC 2020

Algorithm Aims to Help Operators Pair Laser Settings With PAD Lesion Type

L.A. McKeown

February 06, 2020

News Conference News LINC 2020

DCBs Show Consistent Long-term Benefits in Complex Fem-Pop Patient Subsets

L.A. McKeown

January 30, 2020

News Conference News LINC 2020

COMPARE: Similar Efficacy and Safety for Paclitaxel Balloons Regardless of Dose

L.A. McKeown

January 28, 2020

News Conference News VIVA 2019

Nearly 1 Year Later, Endovascular Community Continues to Struggle With Paclitaxel

L.A. McKeown

November 08, 2019

News Conference News TCT 2019

LEVANT: Patient-Level Data Show No Increase in 5-Year Death for Paclitaxel DCBs in PAD

L.A. McKeown

September 28, 2019

News Daily News

FDA Gives Eagerly Awaited Update on Mortality With Paclitaxel-Coated Devices in PAD

Todd Neale

August 07, 2019

Advertisement

Top Endovascular News of 2024

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

Cordis Announces Positive 24-Month Results from Superficial Femoral Artery Study, Confirming Sustained Benefits of SELUTION SLR™ (sustained limus release) Drug-Eluting Balloon in Complex Patients

No Sex-Specific Differences in PAD Therapy Outcomes: REVIVE Analysis

Popliteal Interventions Linked to Higher Long-term Amputation Risk Than SFA

PROSPECT MONSTER: Real-World Data Confirm Low-Dose DCB Efficacy in PAD

TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years

IVUS Useful in Many Peripheral Intervention Scenarios, Consensus Document

Five-Year Paclitaxel DCB Data Attest to Long-term Safety, Efficacy

DISRUPT PAD III: Lithotripsy Prep Linked to Better PAD Patency at 1 Year

Routine IVUS in Peripheral Interventions Supported by Small RCT

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

SAFE-PAD Throws More Doubt on the Paclitaxel Mortality Signal

No Long-term Mortality Risk for Paclitaxel-Based Peripheral Devices: Medicare Advantage Cohort

Algorithm Aims to Help Operators Pair Laser Settings With PAD Lesion Type

DCBs Show Consistent Long-term Benefits in Complex Fem-Pop Patient Subsets

COMPARE: Similar Efficacy and Safety for Paclitaxel Balloons Regardless of Dose

Nearly 1 Year Later, Endovascular Community Continues to Struggle With Paclitaxel

LEVANT: Patient-Level Data Show No Increase in 5-Year Death for Paclitaxel DCBs in PAD

FDA Gives Eagerly Awaited Update on Mortality With Paclitaxel-Coated Devices in PAD

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content